No connection

Search Results

TLRY

BEARISH
$7.15 Live
Tilray Brands, Inc. · NASDAQ
Target $10.04 (+40.5%)
$3.5 52W Range $23.2
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 21, 2026
Market cap
$833.32M
P/E
N/A
ROE
-63.2%
Profit margin
-156.7%
Debt/Equity
0.64
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
90%
Tilray Brands exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating a company in financial distress. The firm suffers from catastrophic profitability metrics, including a profit margin of -156.66% and a total failure to beat earnings estimates in the last four quarters (0/4). While a strong current ratio of 2.79 provides a temporary liquidity buffer, the long-term trajectory is characterized by massive value destruction, with a 5-year price decline of 95.8%. The disconnect between the 'Buy' analyst consensus and the deterministic health scores suggests the stock is being traded on speculative regulatory hopes rather than operational performance.

Key Strengths

Strong short-term liquidity with a Current Ratio of 2.79
Low Price-to-Sales ratio (0.97) suggesting revenue is not overvalued
Manageable Debt/Equity ratio of 0.64
Positive Q/Q revenue growth of 11.28% indicating a potential short-term pivot
Analyst target price ($10.04) suggests potential upside if catalysts materialize

Key Risks

Extreme negative profit margins (-156.66%) and ROE (-63.16%)
Consistent earnings misses with an average surprise of -76.47% over the last 4 quarters
Negative Year-over-Year revenue growth (-7.80%)
Severe fundamental decay as evidenced by a Piotroski F-Score of 1/9
Catastrophic long-term price performance (-95.8% over 5 years)
AI Fair Value Estimate
Based on comprehensive analysis
$6.0
-16.1% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
19
Weak
Value
40
Future
30
Past
10
Health
15
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 1/9, Negative Profit Margins, Consistent Earnings Misses, Long-term Value Destruction
Confidence
95%
Value
40/100

Graham Number is N/A due to lack of earnings; valuation is purely speculative.

Positives
  • P/S ratio below 1.0
Watchpoints
  • No P/E due to losses
  • P/B of 2.37 is high for a non-profitable entity
Future
30/100

Forward P/E of 26.37 assumes a return to profitability that is not yet supported by data.

Positives
  • Recent Q/Q revenue growth
Watchpoints
  • Negative YoY revenue growth
  • Massive EPS decline (-1100% Q/Q)
Past
10/100

Historical trend shows a persistent inability to scale profitably.

Positives
No standout positives identified.
Watchpoints
  • 5-year return of -95.8%
  • Consistent failure to meet analyst expectations
Health
15/100

Liquidity is the only saving grace; operational health is critical.

Positives
  • Current Ratio 2.79
  • Quick Ratio 1.31
Watchpoints
  • Piotroski F-Score 1/9
  • Negative ROA and ROE
Dividend
0/100

Company is in a growth/survival phase; no capital return to shareholders.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$7.15
Analyst Target
$10.04
Upside/Downside
+40.5%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for TLRY and closest competitors.

Updated 2026-04-20
TLR
Tilray Brands, Inc.
Primary
5Y
-95.8%
3Y
-68.9%
1Y
+58.9%
6M
-54.5%
1M
+15.1%
1W
+6.4%
AMP
Amphastar Pharmaceuticals, Inc.
Peer
5Y
-5.1%
3Y
-51.1%
1Y
-30.7%
6M
-35.2%
1M
-36.4%
1W
-6.0%
MNK
MannKind Corporation
Peer
5Y
-36.3%
3Y
-32.0%
1Y
-40.8%
6M
-46.3%
1M
-1.1%
1W
+6.6%
SPR
ARS Pharmaceuticals, Inc.
Peer
5Y
-78.3%
3Y
+19.2%
1Y
-45.0%
6M
-18.6%
1M
-1.4%
1W
+1.6%
INM
InMode Ltd.
Peer
5Y
-67.3%
3Y
-61.5%
1Y
-4.0%
6M
-11.4%
1M
+3.0%
1W
-1.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
26.37
PEG Ratio
N/A
P/B Ratio
2.37
P/S Ratio
0.97
EV/Revenue
3.63
EV/EBITDA
175.52
Market Cap
$833.32M

Profitability

Profit margins and return metrics

Profit Margin -156.67%
Operating Margin -52.7%
Gross Margin 27.68%
ROE -63.16%
ROA -1.47%

Growth

Revenue and earnings growth rates

Revenue Growth -7.8%
Earnings Growth N/A
Q/Q Revenue Growth +11.28%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.64
Moderate
Current Ratio
2.79
Strong
Quick Ratio
1.31
Good
Cash/Share
$0.95

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q1 2026

Revenue
$0.2B
Gross Margin
26.6%
Op. Margin
-9.6%
Net Margin
-12.9%
Total Assets
$2.1B
Liabilities
$0.5B
Equity
$1.6B
Debt/Equity
0.35x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
116%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-07-28
$N/A
2026-04-01
$-0.24
-76.5% surprise
2026-01-08
$-0.02
2025-10-09
$N/A

Healthcare Sector Comparison

Comparing TLRY against 498 companies in the Healthcare sector (28 bullish, 153 neutral, 317 bearish)
Return on Equity (ROE)
-63.16%
This Stock
vs
-95.47%
Sector Avg
-33.8% (Below Avg)
Profit Margin
-156.67%
This Stock
vs
-15.87%
Sector Avg
+887.2% (Superior)
Debt to Equity
0.64
This Stock
vs
2.89
Sector Avg
-78.0% (Less Debt)
Revenue Growth
-7.8%
This Stock
vs
137.48%
Sector Avg
-105.7% (Slower)
Current Ratio
2.79
This Stock
vs
4.66
Sector Avg
-40.1% (Weaker)

Similar Companies

Peer comparison within the same industry

TLRY Tilray Brands, Inc.
BEARISH
Mkt Cap
$833M
P/E
-
ROE
-63.2%
Price
$7.15
AMPH Amphastar...
BEARISH
Mkt Cap
$835M
P/E
9.0
ROE
12.9%
Price
$18.18
 Compare with TLRY
MNKD MannKind Corporation
BEARISH
Mkt Cap
$846M
P/E
137.0
ROE
-%
Price
$2.74
 Compare with TLRY
SPRY ARS...
BEARISH
Mkt Cap
$812M
P/E
-
ROE
-92.3%
Price
$8.18
 Compare with TLRY
INMD InMode Ltd.
NEUTRAL
Mkt Cap
$857M
P/E
9.5
ROE
13.5%
Price
$13.53
 Compare with TLRY

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

COHEN STEVEN MICHAEL
Director
Option Exercise
2026-01-07
12,438 shares · $111,818
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
FORM 8-K
2026-04-15

Tilray Brands, Inc. filed an 8-K, likely announcing its quarterly financial results or a material corporate update.

8-K
8-K
2026-04-15

Tilray Brands, Inc. filed an 8-K on April 15, 2026, likely to announce its quarterly financial results.

8-K
FORM 8-K
2026-04-01

Tilray Brands, Inc. filed an 8-K on April 1, 2026, likely to announce its quarterly financial results.

10-Q
FORM 10-Q
2026-04-01

Tilray Brands (TLRY) filed its Form 10-Q on April 1, 2026. While the filing includes a section for risk factors under Item 1A, no specific financial highlights or detailed risk descriptions were provided in the available excerpt.

8-K
FORM 8-K
2026-03-02
10-Q
FORM 10-Q
2026-01-08

Tilray Brands (TLRY) filed its Form 10-Q on January 8, 2026. While the filing includes a section for risk factors under Item 1A, no specific financial highlights or detailed risk disclosures were provided in the available excerpt.

8-K
FORM 8-K
2026-01-08

Tilray Brands, Inc. filed a Form 8-K on January 8, 2026, to report a material corporate event.

8-K
FORM 8-K
2025-11-26
8-K
FORM 8-K
2025-11-19
8-K
FORM 8-K
2025-11-17

Tilray Brands, Inc. filed an 8-K on November 17, 2025, likely to announce its quarterly financial results.

10-Q
FORM 10-Q
2025-10-09
8-K
FORM 8-K
2025-10-09
DEF 14A
DEF 14A
2025-09-26
8-K
FORM 8-K
2025-09-10
10-K
FORM 10-K
2025-07-29
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
9 analysts
Roth Capital
2026-04-02
up
Neutral Buy
TD Cowen
2026-03-30
Maintains
Buy Buy
Roth Capital
2026-01-20
Maintains
Neutral Neutral

Past News Coverage

Recent headlines mentioning TLRY from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile